30-day average of 13 articles · scale −100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cencora news is Bullish (+60)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+41).
Cencora stock sets specialty-led path for fiscal 2027
AI-generated analysis
Key insights
📈 Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
💰 Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.
🔄 The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.
💵 Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.
🚀 Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.
🤝 The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.
📈 Bullish signals
💰Cencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
💵The company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
🔄Management expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
🚀Cencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
💰The acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Article
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology.
Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas.
For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cencora Inc. (COR) shares gained value after the company raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 17.75 to 17.95, effective August 5, 2026. This upward revision follows strong fiscal third-quarter 2026 results where revenue grew 5.1% year-over-year to reach USD 84.8 billion, while adjusted EPS climbed 12.0% to USD 4.48, significantly beating analyst consensus forecasts.
Market data indicates that Cencora stock is trading at approximately 15.55 times forward earnings as of mid-September 2026. The company has executed roughly USD 1 billion in share buybacks recently and maintains a modest dividend yield of 0.73%, reflecting a strategy focused on reinvesting cash flow and reducing share count to support EPS growth.
Analysts note that while the revenue growth is solid, Cencora operates with thin net margins of 0.79% in the third quarter and high leverage, which are typical for large-scale pharmaceutical distribution but require strict operational discipline. Future performance remains dependent on broader healthcare environment factors such as prescription volumes, pricing stability, and regulatory changes.
📈 Cencora raised full-year adjusted EPS guidance to USD 17.75–17.95.
Cencora (NYSE: COR) reported a strong fiscal third quarter with revenue rising 5.1% to $84.8 billion and adjusted earnings per share climbing 12.0% to $4.48. Management raised its full-year adjusted EPS outlook to between $17.75 and $17.95, while the company accelerated its capital return program by completing a $1 billion stock buyback in a single quarter. Additionally, the board declared a quarterly dividend of $0.60.
The profit growth outpaced sales growth significantly, with adjusted operating income surging 17.0% versus 5.1% revenue growth. This margin expansion was driven largely by a 23.2% jump in gross profit and a widening adjusted gross margin to 4.16%, aided by the OneOncology acquisition. Both US Healthcare Solutions and International Healthcare Solutions posted double-digit operating income increases, though international performance outperformed the domestic segment.
However, the company faces structural headwinds including higher operating expenses rising 26.8% due to integration costs from the OneOncology deal, which now accounts for a larger share of total revenue. Financing costs have also increased with net interest expense up $58.9 million year-over-year as the company funded acquisitions with new debt. Furthermore, lower-margin GLP-1 drug sales and the loss of a significant oncology customer are creating drag on overall profitability.
Analyst sentiment remains mixed regarding the sustainability of these margin gains once acquisition-related expenses normalize. While hedge fund ownership increased slightly to 63 funds, the stock trades at 15.55 times forward earnings. The company's future performance will depend on whether it can maintain its expanded margins amidst rising interest costs and a sales mix increasingly weighted toward lower-margin pharmaceutical products.
📈 Cencora raised full-year EPS guidance to $17.75-$17.95 after 12% YoY earnings growth.
💰 Company completed a $1 billion stock buyback ahead of its annual target.
🏥 OneOncology acquisition boosted margins but added significant debt financing costs and expenses.
⚠️ Lower-margin GLP-1 drug sales are diluting overall profitability despite revenue additions.
📉 Loss of major oncology customer negatively impacted US revenue in 2025.
📈 Cencora raised full-year adjusted EPS guidance to $17.75-$17.95 following a 12.0% year-over-year increase in adjusted earnings per share to $4.48.
💰 The company accelerated its capital return strategy by completing a $1 billion stock buyback in the quarter, ahead of its original calendar-year target.
📊 Adjusted operating income surged 17.0% while revenue grew 5.1%, driven by a 23.2% increase in gross profit and a margin expansion to 4.16%.
🏥 The OneOncology acquisition contributed significantly to US business growth, lifting margins but also adding substantial operating expenses and debt financing costs.
⚠️ Operating expenses jumped 26.8%, outpacing gross profit growth, as the company integrates higher-cost oncology operations into its existing business model.
📉 Net interest expense rose $58.9 million year-over-year due to new senior notes and variable-rate term loans used to fund acquisitions.
🧬 Lower-margin GLP-1 drug sales for diabetes and weight loss are diluting overall profitability as these products add revenue but less profit per dollar.
📉 Cencora lost a major oncology customer in 2025, which negatively impacted US revenue alongside lower sales to a large mail-order pharmaceutical customer.
🏦 Hedge fund ownership increased slightly to 63 funds from 61, indicating modest institutional interest despite the stock trading at 15.55 times forward earnings.
💸 The board declared a $0.60 quarterly dividend payable August 31 to holders of record on August 14.
Bullish Signals
EPS guidance raised to $17.75-$17.95.
Completed $1B stock buyback in one quarter.
Gross margin expanded 61 bps to 4.16%.
International operating income up 20.8%.
US operating income grew 15.9%.
Risk Factors
Operating expenses rose 26.8% amid OneOncology integration costs.
Net interest expense increased $58.9M, weighing on profitability.
Sales mix shift to lower-margin GLP-1 drugs reduces profit.
Lost oncology customer in 2025 impacted US revenue.
Cencora raised its full-year adjusted EPS guidance to $17.75-$17.95, signaling management confidence in future profitability despite market headwinds.
The company completed a $1 billion stock buyback in a single quarter, demonstrating strong cash flow generation and a commitment to returning capital to shareholders.
Adjusted gross margin expanded 61 basis points to 4.16%, driven by a 23.2% increase in gross profit and successful integration of the OneOncology acquisition.
International Healthcare Solutions delivered robust performance with operating income up 20.8%, highlighting strength in European distribution and global specialty logistics.
US Healthcare Solutions grew operating income by 15.9% on higher pharmaceutical sales, validating the core business model outside of oncology.
Risk Factors
Operating expenses increased 26.8%, significantly outpacing gross profit growth, as the OneOncology acquisition brought substantial integration costs and overhead.
Net interest expense rose $58.9 million year-over-year due to new debt financing, which will weigh on bottom-line profitability in the coming quarters.
The sales mix is shifting toward lower-margin GLP-1 drugs for diabetes and weight loss, reducing the profit contribution per dollar of revenue generated.
Cencora lost a significant oncology customer in 2025, which directly impacted US revenue and offset some gains from other segments.
Lower manufacturer prices on certain brand pharmaceuticals are suppressing revenue growth in the domestic market.
Cencora Inc. stock experienced a volatile trading session on September 17, 2026, closing down approximately 2.8 percent before rebounding in after-hours trading to around USD 327.50. The price action was influenced by a recent insider transaction where director Lon R. Greenberg sold 1,280 shares for roughly USD 411,264, signaling that management is monetizing gains following a strong run.
Financially, the company reported year-over-year earnings per share growth from USD 4.00 to USD 4.48, representing a 12 percent increase. However, this EPS expansion outpaced revenue growth of 5.1 percent, indicating that the improvement was driven primarily by operational leverage and efficiency gains rather than significant pricing power.
Despite the earnings beat, Cencora maintained a net margin below 1 percent, which is consistent with the low-margin profile typical of large pharmaceutical distribution businesses. The options market reflects this volatility with elevated implied volatility for call options at 93.05 percent, suggesting investors are pricing in pronounced short-term swings.
📉 COR stock closed down 2.8% before after-hours rebound to USD 327.50.
💼 Director Lon R. Greenberg sold 1,280 shares for USD 411,264.
📈 EPS rose 12% year-over-year to USD 4.48 driven by operational leverage.
📊 Revenue grew 5.1% while net margin remained below 1%.
🔀 Call options implied volatility stands at 93.05%, signaling high short-term swings.
📉 Cencora stock closed lower by about 2.8 percent on September 17, 2026, before rebounding to USD 327.50 in after-hours trading.
💼 Director Lon R. Greenberg sold 1,280 shares for approximately USD 411,264, indicating insiders are taking profits after a strong rally.
📈 Earnings per share rose 12 percent year-over-year from USD 4.00 to USD 4.48, driven by operational leverage rather than revenue growth.
📊 Revenue increased by 5.1 percent over the same period, showing moderate top-line expansion in the pharmaceutical distribution sector.
💰 The company maintained a net margin below 1 percent, reflecting the low-margin nature of its core business model.
🔀 Options market data shows high implied volatility for call options at 93.05 percent, signaling expectations of significant short-term price swings.
Bullish Signals
EPS rose 12% to $4.48 YoY.
Revenue grew 5.1% via efficiency.
Risk Factors
Net margins stayed below 1% due to industry constraints.
Director Greenberg sold shares after stock price run-up.
Bullish Signals
Cencora achieved a 12 percent year-over-year increase in earnings per share, growing from USD 4.00 to USD 4.48.
The company successfully leveraged operational efficiency to outpace revenue growth with a 5.1 percent increase in total revenue.
Risk Factors
Net margins remained below 1 percent, highlighting the low-margin structural constraints of the pharmaceutical distribution industry.
Insider selling by director Lon R. Greenberg suggests management is monetizing gains after a significant stock price run-up.
Cencora, Inc. (COR) is a large-cap pharmaceutical distributor based in Conshohocken, Pennsylvania, with a market capitalization of $61.6 billion. The company sources and distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies to acute care hospitals and health systems both domestically and internationally.
Recent stock performance shows mixed results depending on the timeframe. Over the past three months, COR shares have risen 18.5%, outperforming the Dow Jones Industrial Average which grew 3.9% during the same period. However, over the last 52 weeks, the stock has surged only 9%, lagging behind the Dow's 16% gain and significantly underperforming its peer Cardinal Health, Inc., which has grown 60% in the past year.
Following the release of Q3 2026 earnings, COR shares rose 3.6%. The company reported quarterly revenue of $84.8 billion, which missed Wall Street estimates, but adjusted earnings per share (EPS) of $4.48 exceeded forecasts. Analysts maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, suggesting 12.9% upside from current levels.
📈 COR stock rose 18.5% in three months, outperforming Dow's 3.9%.
💰 Q3 revenue missed estimates but adjusted EPS beat forecasts.
📈 COR stock has risen 18.5% over the past three months, outperforming the Dow Jones Industrial Average's 3.9% gain during the same period.
📉 Over the last 52 weeks, COR shares have surged 9%, lagging behind the Dow's 16% gain and significantly underperforming peer Cardinal Health, Inc., which has grown 60%.
💰 Cencora reported Q3 2026 revenue of $84.8 billion, which missed Street estimates, but adjusted EPS of $4.48 topped Wall Street forecasts.
📊 Following the earnings release, COR shares rose 3.6%, indicating positive market reaction to the beat in profitability despite the revenue miss.
🎯 Analysts covering Cencora maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, implying 12.9% upside potential.
📉 The stock has underperformed its primary peer Cardinal Health, Inc., which has seen a 60% stock price increase over the past year.
Bullish Signals
Stock rose 18.5% in three months, outperforming Dow's 3.9%.
Q3 2026 adjusted EPS of $4.48 beat forecasts.
Shares jumped 3.6% after earnings beat.
Analysts rate 'Strong Buy' with $366.50 target.
Risk Factors
Stock underperformed Dow Jones, gaining only 9% vs 16%.
Lags peer Cardinal Health, up 60% in a year.
Bullish Signals
COR stock has risen 18.5% over the past three months, significantly outperforming the Dow Jones Industrial Average's 3.9% gain during the same period.
The company reported adjusted EPS of $4.48 for Q3 2026, which topped Wall Street forecasts despite revenue missing estimates.
Following the earnings release, COR shares rose 3.6%, demonstrating immediate positive investor reaction to the profitability beat.
Analysts maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, suggesting 12.9% upside from current levels.
Risk Factors
COR stock has underperformed the Dow Jones Industrial Average over the past 52 weeks, surging only 9% compared to the index's 16% gain.
The company significantly lags behind its major peer Cardinal Health, Inc., which has grown 60% in stock price over the past year.
Cencora Inc. (COR) shares gained momentum following the release of solid fiscal 2026 results, driven by robust demand in specialty pharmaceuticals and updated full-year guidance. The company reported second-quarter revenue of USD 84.75 billion, marking a 5.1% year-over-year increase as it capitalized on growing demand for specialty care and healthcare solutions both domestically and internationally.
Financial performance exceeded analyst expectations, with adjusted earnings per share reaching USD 4.48, surpassing the consensus estimate of USD 4.35 by approximately 3%. Management maintained an operating margin of about 1.3%, matching the prior-year level, which indicates that the company is expanding earnings through scale and operational efficiency rather than sacrificing profitability in a competitive distribution landscape.
Looking ahead, Wall Street consensus data projects quarterly revenue of roughly USD 84.89 billion and earnings per share of USD 4.37 for the remainder of fiscal 2026, implying continued double-digit growth trajectories. Analysts expect the US Healthcare Solutions segment to remain the primary driver of top-line growth, while International operations are projected to be relatively flat.
Cencora reinforced its commitment to shareholders by conducting approximately USD 1 billion in opportunistic share repurchases during the period. Additionally, the company raised its full-year adjusted earnings per share guidance to a midpoint of USD 17.85, signaling confidence in its long-term earnings power and providing a clear quantitative benchmark for future performance.
📈 Cencora Q2 FY2026 revenue hit USD 84.75B, up 5.1% YoY.
💰 Adjusted EPS reached USD 4.48, beating estimates by 3%.
🚀 Full-year adjusted EPS guidance raised to a midpoint of USD 17.85.
💸 Executed approx USD 1B in opportunistic share repurchases.
🇺🇸 US Healthcare Solutions projected to drive top-line growth at USD 75B.
📈 Cencora reported second-quarter fiscal 2026 revenue of USD 84.75 billion, representing a 5.1% year-over-year growth driven by specialty pharmaceutical demand.
💰 Adjusted earnings per share reached USD 4.48 in the quarter, beating consensus estimates of USD 4.35 by roughly 3%.
📊 Management maintained an operating margin of about 1.3%, matching the previous year's level to demonstrate efficiency gains without sacrificing profitability.
🚀 The company raised its full-year adjusted earnings per share guidance for fiscal 2026 to a midpoint of USD 17.85.
💸 Cencora executed approximately USD 1 billion in opportunistic share repurchases, signaling management confidence in long-term earnings power.
🇺🇸 US Healthcare Solutions is projected to generate around USD 75 billion in quarterly revenue, serving as the primary driver of top-line growth.
🌍 International Healthcare Solutions revenue is expected to remain flat at approximately USD 7.79 billion per quarter for fiscal 2026.
💊 Specialty pharmaceuticals remain a central pillar of Cencora's business model, offering tailored distribution and services to complex-care providers.
📉 Analyst consensus expects quarterly earnings of USD 4.37 per share, implying a projected 9.3% increase versus the same quarter a year earlier.
🏢 Management Services Organisations serving networks like OneOncology and RCA contributed significantly to revenue and earnings momentum in the second quarter.
Bullish Signals
Revenue grew 5.1% YoY to USD 84.75B.
EPS beat estimates at USD 4.48.
Raised full-year guidance to USD 17.85 midpoint.
Repurchased USD 1B in shares.
US Healthcare Solutions revenue projected at USD 75B.
Bullish Signals
Cencora reported second-quarter fiscal 2026 revenue of USD 84.75 billion, representing a solid 5.1% year-over-year growth driven by strong demand in specialty care.
Adjusted earnings per share reached USD 4.48, beating consensus estimates of USD 4.35 by roughly 3%, highlighting profitability tracking ahead of expectations.
The company raised its full-year adjusted earnings per share guidance for fiscal 2026 to a midpoint of USD 17.85, framing positive investor expectations.
Management conducted approximately USD 1 billion in opportunistic share repurchases, signaling confidence in the company's long-term earnings power and supporting equity value.
Operating margins remained stable at about 1.3%, demonstrating that the group is expanding earnings through scale and efficiency rather than sacrificing margin.
US Healthcare Solutions revenue is projected to reach around USD 75 billion for the quarter, confirming it remains the primary driver of top-line growth.
Specialty pharmaceuticals continue to serve as a strategic pillar, anchoring the stock in a less commoditized part of the healthcare value chain with resilient earnings potential.
Zenith Epigenetics Ltd. (COR) announced a strategic collaboration with Cencora, formerly AmerisourceBergen, to accelerate the commercialization of its lead compound, ZEN-3694. This partnership focuses on strategizing market introduction, evaluating regulatory and market access barriers, and designing patient access programs to maximize the therapeutic's potential in oncology.
Zenith Epigenetics is a clinical-stage biotechnology company developing novel BET inhibitor combinations for cancer treatment. The collaboration leverages Cencora's extensive distribution capabilities and healthcare experience to support Zenith's pre-commercial launch preparations and optimize time-to-market for ZEN-3694.
ZEN-3694 is currently in clinical development across numerous oncologic indications, including metastatic castration-resistant prostate cancer, ovarian cancer, and various solid tumors. The program features randomized phase 2b trials and phase 1/2 studies sponsored by major institutions like the National Cancer Institute, often in combination with established therapies from partners such as Pfizer, Merck, and Eli Lilly.
The agreement underscores Zenith's strong network of collaborators, which includes major pharmaceutical giants and leading academic medical centers. This partnership aims to bring ZEN-3694 into the lives of patients nationwide and globally, positioning Zenith Epigenetics for potential future commercial success in the competitive oncology landscape.
🤝 COR partners with Cencora to accelerate ZEN-3694 commercialization.
🔬 ZEN-3694 enhances efficacy of marketed cancer drugs for prostate, ovarian, and lung cancers.
🏥 COR maintains robust clinical trials for ZEN-3694 across multiple oncologic indications.
💼 Cencora provides integrated support to bring ZEN-3694 innovations to market faster.
🤝 Zenith Epigenetics enters a collaboration with Cencora to accelerate the commercialization strategy for its lead compound ZEN-3694.
📈 The partnership focuses on evaluating regulatory pathways, market access opportunities, and designing patient adherence programs for ZEN-3694.
🔬 ZEN-3694 is an advanced epigenetic approach designed to synergistically advance the efficacy of currently marketed cancer drugs.
🏥 Zenith Epigenetics maintains a robust portfolio of clinical trials for ZEN-3694 across multiple oncologic indications including prostate, ovarian, and lung cancers.
🤝 Major pharmaceutical partners such as Pfizer, Merck, BMS, Eli Lilly, and Astellas are already involved in the development of ZEN-3694.
🎓 The ZEN-3694 program is supported by prestigious research institutions including the National Cancer Institute, Dana-Farber, Yale, and Memorial Sloan Kettering.
💼 Cencora will provide integrated support across the clinical and commercialization journey to help Zenith bring innovations to market faster.
🚀 Zenith Epigenetics aims to innovate the future of oncology by bringing ZEN-3694 into patients' homes globally through this strategic alliance.
Bullish Signals
Zenith Epigenetics secures a strategic collaboration with Cencora, a Fortune 500 leader in pharmaceutical solutions, to accelerate the commercialization of its lead compound ZEN-3694.
The partnership leverages Cencora's unmatched distribution capabilities and global impact to optimize market access and time-to-market for Zenith's novel therapeutics.
Zenith Epigenetics demonstrates a strong collaborative network with major pharmaceutical giants including Pfizer, Merck, BMS, Eli Lilly, and Astellas for its ZEN-3694 program.
The company has secured support from top-tier research institutions like the National Cancer Institute, Dana-Farber, and Memorial Sloan Kettering to advance multiple clinical trials for ZEN-3694.
Zenith Epigenetics is developing a novel epigenetic approach designed to synergistically enhance the efficacy of existing marketed cancer drugs, addressing significant unmet medical needs.
Cencora Inc. shares gained value following the company's announcement of raised fiscal 2026 guidance and robust third-quarter earnings results. The stock traded near its recent high as investors reacted positively to year-on-year revenue growth and higher earnings per share reported for Q3 2026, which support the optimistic full-year outlook.
In addition to strong financial performance, Cencora expanded its service portfolio by launching a new cell and gene therapy enablement service. This initiative is offered through its Accelerate Pharmacy Solutions business unit and is designed to assist health systems in managing the logistical and clinical complexities associated with advanced therapies.
The company aims to streamline logistics, reimbursement processes, and clinical coordination for cell and gene therapies, positioning itself to capture growing demand in this specialized segment. Market data indicates institutional interest remains strong, with shares trading close to the average analyst target price, suggesting moderate upside potential based on current market conditions.
📈 Cencora raised fiscal 2026 guidance on strong core business momentum.
🚀 COR launched new cell and gene therapy enablement services via Accelerate Pharmacy Solutions.
💵 COR stock opened at $336.77, near the $370.85 average analyst target price.
📊 Institutional buying supports confidence in COR's earnings strength and expansion.
📈 Cencora Inc. raised its fiscal 2026 guidance driven by strong momentum in its core pharmaceuticals distribution and services business.
💰 The company reported year-on-year revenue growth and higher earnings per share for the third quarter of fiscal 2026 compared to the prior-year period.
🚀 Cencora launched a new cell and gene therapy enablement service through its Accelerate Pharmacy Solutions business to help health systems manage advanced therapies.
🏥 The new initiative aims to streamline logistics, reimbursement, and clinical coordination for cell and gene therapies to capture growing market demand.
💵 Cencora stock opened at 336.77 USD on September 4, 2026, trading near the average analyst target price of 370.85 USD.
📊 Institutional buying activity supports investor confidence in the company's recent earnings strength and strategic expansion.
Bullish Signals
Raised fiscal 2026 guidance on strong core business momentum.
Delivered YoY revenue growth and higher EPS in Q3 2026.
Launched new cell and gene therapy enablement service.
Aims to capture growing demand in advanced therapies segment.
Shares trading near recent high on strong results.
Bullish Signals
Cencora Inc. raised its fiscal 2026 guidance on the back of strong momentum in its core pharmaceuticals distribution and services business.
The company delivered year-on-year revenue growth and higher earnings per share for the third quarter of fiscal 2026 compared to the prior-year period.
Cencora launched a new cell and gene therapy enablement service through its Accelerate Pharmacy Solutions business to help health systems manage advanced therapies.
The new initiative aims to streamline logistics, reimbursement, and clinical coordination for cell and gene therapies, positioning the company to capture growing demand in this segment.
Shares of Cencora Inc. are trading near their recent high as investors digest higher 2026 guidance and robust Q3 earnings.
Cencora Inc. shares gained value following the release of strong third-quarter fiscal 2026 earnings and a subsequent raise in full-year guidance for the same period. The company reported year-over-year revenue growth and increased earnings per share, driven by robust momentum within its core pharmaceuticals distribution and services business. This financial strength has bolstered investor confidence, with the stock trading near recent highs and approaching analyst target prices.
Beyond traditional logistics, Cencora is expanding its strategic capabilities by launching a new cell and gene therapy enablement service through its Accelerate Pharmacy Solutions division. This initiative is designed to assist health systems in managing the logistical and clinical complexities associated with advanced therapies. By streamlining reimbursement processes and clinical coordination, the company aims to capture growing demand in this specialized segment of the healthcare market.
The stock opened at $336.77 on September 4, 2026, reflecting positive market sentiment regarding both its immediate financial performance and long-term growth prospects in advanced therapy logistics. Analysts view the combination of strong Q3 results and the new service launch as supportive of moderate upside potential relative to current valuation levels.
📈 Raised fiscal 2026 guidance after strong Q3 revenue and EPS growth.
💊 Launched new cell/gene therapy enablement service via Accelerate Pharmacy Solutions.
🚀 New initiative streamlines logistics to capture advanced therapy market demand.
📊 Shares opened at $336.77, trading below $370.85 analyst target price.
🏭 Operates large distribution center supporting core business growth and expansion.
📈 Cencora Inc. raised its fiscal 2026 guidance following a strong third quarter characterized by year-over-year revenue growth and higher earnings per share.
💊 The company launched a new cell and gene therapy enablement service via its Accelerate Pharmacy Solutions business to help health systems manage advanced therapies.
🚀 This new initiative aims to streamline logistics, reimbursement, and clinical coordination, positioning Cencora to capture demand in the growing advanced therapy market.
📊 Shares of Cencora Inc. opened at $336.77 on September 4, 2026, trading near recent highs as investors digested the positive earnings and guidance update.
🎯 The stock is currently trading below the average analyst target price of $370.85, suggesting moderate upside potential according to market data.
🏭 Cencora continues to operate a large pharmaceutical distribution center with extensive logistics capabilities supporting its core business growth.
Bullish Signals
Raised fiscal 2026 guidance on strong core business momentum.
Bullish Signals
Cencora Inc. raised its fiscal 2026 guidance supported by strong momentum in its core pharmaceuticals distribution and services business.
The company delivered year-over-year revenue growth and higher earnings per share in the third quarter of fiscal 2026.
Cencora launched a new cell and gene therapy enablement service to help health systems manage the complexity of advanced therapies.
The new initiative aims to streamline logistics, reimbursement, and clinical coordination for cell and gene therapies, targeting growing market demand.
Shares opened at $336.77 on September 4, 2026, trading firmly near recent highs following the positive earnings report.
Cencora (COR) is a leading global pharmaceutical service company with a market capitalization of $64.19 billion, focusing on drug distribution and healthcare solutions to reduce costs and improve patient outcomes. The company's U.S. Healthcare Solutions business demonstrated accelerating momentum in the fiscal third quarter, with revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million, driven by strength in specialty segments.
Key growth drivers include the OneOncology acquisition, which is performing above expectations and serving as a long-term platform for clinical trials and new services, alongside robust international operations where revenues grew 6% and operating income rose 21%. Additionally, Cencora is capitalizing on structural volume opportunities from GLP-1 demand, which saw a $2.3 billion year-over-year increase in sales, and the expanding market for Part B biosimilars.
Despite positive underlying performance, Cencora faces headwinds including manufacturer list-price reductions that suppressed headline revenue growth by $2.4 billion in the quarter, offsetting the GLP-1 gains. The company also anticipates a potential earnings reset in fiscal 2027 due to the divestiture of its MWI Animal Health business to Covetrus, which is expected to create an approximate $150 million operating-income headwind. Regulatory uncertainty regarding 340B and ASP rules remains a persistent risk to specialty economics.
Analyst consensus estimates for fiscal 2026 show improving trends, with earnings expectations revised north to $17.79 per share and revenue pegged at $88.09 billion, implying year-over-year growth of 5.2%. While the stock has underperformed the S&P 500 year-to-date, management expects full-year U.S. revenue growth in the lower half of its 4-6% guided range as it fully laps prior oncology customer losses and benefits from easier expense comparisons.
📈 U.S. Healthcare Solutions revenue rose 5% to $74.9B with operating income up 16%.
🚀 OneOncology acts as a long-term growth platform progressing through its value-creation plan.
💉 GLP-1 demand drove a $2.3B sales increase in U.S. Healthcare Solutions.
📉 Manufacturer list-price cuts created a $2.4B headwind offsetting Q3 incremental sales.
⚠️ Pending MWI Animal Health divestiture may cause ~$150M operating income headwind by 2027.
📈 Cencora's U.S. Healthcare Solutions business showed accelerating momentum with fiscal third-quarter revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million.
🚀 OneOncology is emerging as a meaningful long-term growth platform, performing modestly above expectations with a three-phase value-creation plan progressing through integration and new services.
🌍 International Healthcare Solutions revenues increased 6% to $7.7 billion, while operating income rose 21%, driven by World Courier stabilization and European 3PL growth.
💉 GLP-1 demand is becoming a significant structural volume driver, with U.S. Healthcare Solutions recording a $2.3 billion year-over-year increase in sales.
📉 Manufacturer list-price reductions remain a major drag on headline revenue, creating a $2.4 billion headwind that offset the incremental GLP-1 sales in the fiscal third quarter.
⚠️ The pending divestiture of MWI Animal Health to Covetrus could create an approximately $150 million operating-income headwind within Other starting around fiscal 2027.
📊 Analyst consensus estimates for fiscal 2026 earnings have moved north to $17.79 per share, reflecting a stable improving revision trend over the past 30 days.
🔮 Management expects full-year U.S. revenue growth in the lower half of its 4-6% guided range as it laps prior oncology customer losses and benefits from easier expense comparisons.
⚖️ Regulatory uncertainty regarding proposed changes to 340B and ASP rules remains a persistent risk that could vary across Cencora's broad customer base.
💵 The company has a market capitalization of $64.19 billion and is one of the world's largest pharmaceutical service companies focused on drug distribution.
Bullish Signals
Cencora's U.S. Healthcare Solutions business showed accelerating underlying momentum with fiscal third-quarter revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million.
OneOncology is performing modestly above expectations and serves as a meaningful long-term growth platform for clinical trials and new services beyond initial distribution benefits.
International Healthcare Solutions revenues increased 6% to $7.7 billion while operating income rose 21%, providing a diversified earnings stream with double-digit growth from World Courier and European 3PL.
GLP-1 demand is becoming an important structural volume driver, with U.S. Healthcare Solutions recording a $2.3 billion year-over-year increase in sales broadly in line with expectations.
Cencora's specialty-centric model is well-positioned to benefit from pharmaceutical innovation, including biosimilars and complex therapies, particularly Part B biosimilars which offer favorable profit opportunities.
Analyst consensus estimates for fiscal 2026 earnings have improved, moving north 8 cents to $17.79 per share in the past 30 days, indicating a stable improving revision trend.
Risk Factors
Manufacturer list-price reductions remain a major drag on headline revenue growth, creating a $2.4 billion headwind in the fiscal third quarter that offset incremental GLP-1 sales.
The pending divestiture of MWI Animal Health to Covetrus is expected to create an approximately $150 million operating-income headwind within Other if it closes around the midpoint of fiscal 2027.
Regulatory and pricing uncertainty regarding proposed changes to 340B and ASP rules remains a persistent risk that could pressure Cencora's specialty and distribution economics.
Cencora (COR) reported a robust fiscal third quarter for 2026, delivering adjusted diluted earnings per share of $4.48, a 12.0% year-over-year increase, and revenue of $84.75 billion, up 5.1%. This performance marks the fifth consecutive quarter where the company exceeded consensus EPS estimates, driven significantly by the February 2026 acquisition of OneOncology.
The acquisition of OneOncology expanded U.S. Healthcare Solutions gross profit margins to 3.17% from 2.54% and boosted segment operating income by 15.9% to $966.18 million. While the deal necessitated raising debt to $4.50 billion, increasing net interest expense by 72.0% to $140.71 million, broader growth in specialty pharmaceutical distribution, rising GLP-1 sales, and international expansion offset these costs.
Management raised its full-year fiscal 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95 and projected revenue growth between 4% and 6%. The company expects adjusted operating income to grow 13% to 14%, with specific targets set for U.S., International, and Other segments, signaling strong confidence in sustaining momentum through the fiscal year-end.
Additional financial highlights include a LIFO credit of $94.3 million, a $102.0 million reduction in opioid liability following dismissed litigation, and projected adjusted free cash flow of approximately $3.0 billion against capital expenditures of roughly $900 million for the full year.
📈 Q3 EPS rose 12% YoY to $4.48.
💰 Revenue grew 5.1% to $84.75 billion.
🏆 Beat consensus EPS estimates for five quarters.
🔬 OneOncology acquisition boosted U.S. Healthcare margins.
📈 Raised full-year EPS guidance to $17.75-$17.95.
📈 Cencora reported Q3 2026 adjusted diluted EPS of $4.48, representing a 12.0% year-over-year increase.
💰 Revenue reached $84.75 billion in the quarter, marking a 5.1% growth compared to the prior year.
🏆 The company extended its streak of beating consensus EPS estimates to five consecutive quarters.
🔬 The February 2026 acquisition of OneOncology was the primary driver behind improved gross profit margins in U.S. Healthcare Solutions.
💵 Gross profit margins for U.S. Healthcare Solutions expanded to 3.17% from 2.54% following the oncology integration.
📊 Segment operating income for U.S. Healthcare Solutions surged 15.9% to $966.18 million in Q3 2026.
💸 Net interest expense increased 72.0% to $140.71 million due to $4.50 billion in debt raised for the OneOncology deal.
🌍 International operating income grew 20.8% driven by European distribution and global specialty logistics expansion.
💉 Rising sales of GLP-1 products for diabetes and weight loss contributed to overall revenue strength.
📈 Management raised full-year fiscal 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95.
🎯 Full-year revenue is expected to grow between 4% and 6%, with operating income growth targeted at 13% to 14%.
💰 A LIFO credit of $94.3 million was recorded in Q3 2026, compared to $52.1 million in the same quarter last year.
⚖️ The company recognized a $102.0 million reduction in opioid liability after dismissing related litigation.
📉 Adjusted free cash flow is projected to be approximately $3.0 billion for fiscal 2026.
🏗️ Capital expenditures are expected to total approximately $900 million for the full year.
Bullish Signals
EPS rose 12.0% to $4.48.
Revenue grew 5.1% to $84.75B.
Gross margins improved to 3.17%.
U.S. operating income up 15.9% to $966.18M.
International operating income surged 20.8%.
EPS guidance raised to $17.75-$17.95.
Opioid liability reduced by $102.0M.
Projected free cash flow hits $3.0B.
Risk Factors
Net interest expense rose 72% to $140.71 million.
$4.5 billion debt incurred for OneOncology acquisition.
High interest costs may pressure net income margins.
Bullish Signals
Cencora achieved a 12.0% year-over-year increase in adjusted diluted EPS to $4.48, demonstrating strong profitability growth.
Revenue grew by 5.1% to reach $84.75 billion, indicating robust top-line expansion across the business.
The acquisition of OneOncology successfully expanded U.S. Healthcare Solutions gross profit margins to 3.17%, improving overall efficiency.
Segment operating income in U.S. Healthcare Solutions increased by 15.9% to $966.18 million, reflecting successful integration.
International operations showed strong momentum with a 20.8% increase in operating income driven by European and global logistics growth.
Management raised full-year fiscal 2026 EPS guidance to $17.75-$17.95, signaling confidence in future performance.
The company secured a significant $102.0 million reduction in opioid liability following the dismissal of litigation, improving net position.
Projected adjusted free cash flow of $3.0 billion highlights strong liquidity generation capabilities for the fiscal year.
Risk Factors
Net interest expense rose sharply by 72.0% to $140.71 million due to $4.50 billion in debt incurred to finance the OneOncology acquisition.
The substantial increase in interest costs may pressure net income margins if revenue growth does not fully offset financing expenses.
Cencora Inc., formerly AmerisourceBergen, is a dominant player in the US pharmaceutical distribution sector alongside McKesson and Cardinal Health. The company manages the logistics of branded, generic, and specialty medicines for a vast network including retail chains, hospitals, and independent pharmacies. Its operations are critical to patient care, relying on reliable supply chain management, regulatory compliance, and inventory control.
Beyond standard wholesale, Cencora offers specialized services such as market access support, reimbursement assistance, and logistics for temperature-sensitive products through its World Courier division. The firm has also expanded internationally via the acquisition of Alliance Healthcare, strengthening its European pharmaceutical wholesale capabilities. Its business model extends into veterinary health through the MWI Animal Health segment.
Recent market data indicates a positive outlook driven by analyst sentiment and insider activity. Approximately 58% of analysts rate the stock as a Buy, with no recent rating changes recorded over the last month. Insider buying has been significant, with net purchases totaling approximately $2.3 million in Cencora stock over the past 90 days.
Technical analysis presents a mixed but cautiously optimistic picture for the near term. While moving-average signals do not indicate a clear long-term trend yet, the Relative Strength Index (RSI) is currently showing bullish momentum. Overall, the combination of positive analyst ratings and sustained insider buying supports a constructive view on the company's immediate trajectory.
🏢 Cencora dominates US pharmaceutical wholesale alongside McKesson and Cardinal Health.
💊 Distributes branded, generic, and specialty medicines to hospitals and retail pharmacies.
🌍 Acquired Alliance Healthcare to strengthen European pharmaceutical distribution capabilities.
🚀 World Courier offers global logistics for clinical trials and temperature-controlled products.
🐾 MWI Animal Health extends distribution into the veterinary market.
🏢 Cencora operates as a major pharmaceutical distributor alongside McKesson and Cardinal Health, controlling a vast majority of domestic wholesale activity.
💊 The company sources and distributes branded, generic, and specialty medicines to retail pharmacies, hospitals, clinics, and mail-order providers.
🌍 International expansion was achieved through the acquisition of Alliance Healthcare, strengthening its position in European pharmaceutical wholesale.
🚀 World Courier provides recognized global logistics services for clinical trials and biopharma supply chains, including temperature-controlled products.
🐾 The MWI Animal Health business extends Cencora's distribution model into the veterinary and animal health markets.
📈 Analyst sentiment is positive with 58% of analysts currently rating Cencora as a Buy.
💰 Insiders were net buyers of approximately $2.3M in Cencora stock over the last 90 days, signaling confidence.
📊 Technical signals are mixed regarding long-term trends, but the RSI indicator is currently bullish for the near term.
🔍 No recent news events have been linked to this specific listing in the immediate period.
Bullish Signals
58% analysts rate Cencora as Buy.
Bullish Signals
Analyst sentiment is positive with 58% of analysts rating Cencora as a Buy.
Insider buying activity is strong, with net purchases of approximately $2.3 million over the last 90 days.
Technical indicators show bullish momentum in the Relative Strength Index (RSI) for the near term.
Cencora holds a dominant market position alongside McKesson and Cardinal Health, controlling the vast majority of domestic pharmaceutical wholesale activity.
Arrowstreet Capital Limited Partnership reduced its stake in Cencora, Inc. (NYSE:COR) by 16.5% during the first quarter, selling 205,966 shares to hold 1,042,002 shares valued at $327.3 million. While Arrowstreet decreased its position, several other institutional investors increased their holdings in the fourth quarter, including JFS Wealth Advisors LLC which grew its stake by 30.2% and Accent Capital Management LLC which raised its position by 36.1%. Corporate insider Lauren M. Tyler also purchased 550 shares for approximately $148,626 on June 22nd, increasing her direct ownership to 4,359 shares.
Cencora reported first-quarter earnings of $4.75 per share, missing analyst consensus estimates of $4.82 by seven cents. Revenue came in at $78.36 billion, falling short of the $81.09 billion forecasted by analysts, though it represented a 3.9% year-over-year increase. The company maintained strong financial metrics with a return on equity of 135.20% and a net margin of 0.78%. For fiscal year 2026, the company has provided EPS guidance ranging between $17.65 and $17.90.
In strategic developments, Cencora's Board of Directors authorized a new share buyback plan allowing the repurchase of up to $2.00 billion in shares, representing approximately 3.9% of its outstanding stock. The company also recently paid a quarterly dividend of $0.60 per share to stockholders of record as of May 15th, resulting in an annualized dividend yield of 0.8%. Analysts have issued mixed ratings with price targets ranging from $280 to $420, averaging around $367.75.
📉 Arrowstreet sold 205,966 shares, reducing stake by 16.5%.
💰 Q1 revenue hit $78.36 billion, missing analyst estimates.
📊 EPS of $4.75 missed consensus by seven cents.
💼 Board authorized new $2.00 billion share buyback program.
💵 Quarterly dividend is $0.60 with 0.8% annualized yield.
📉 Arrowstreet Capital Limited Partnership decreased its stake in Cencora by 16.5% in Q1, selling 205,966 shares while retaining a position worth $327.3 million.
📈 JFS Wealth Advisors LLC increased its holdings by 30.2% in Q4, and Accent Capital Management LLC raised its stake by 36.1% during the same period.
💰 Cencora reported Q1 revenue of $78.36 billion, which was lower than the analyst estimate of $81.09 billion despite a 3.9% year-over-year growth.
📊 The company posted earnings per share of $4.75, missing the consensus estimate of $4.82 by seven cents.
💼 Cencora's Board authorized a new share buyback program allowing the repurchase of up to $2.00 billion in shares.
💵 The company paid a quarterly dividend of $0.60 per share, establishing an annualized yield of 0.8% and a payout ratio of 18.40%.
👩💼 Director Lauren M. Tyler purchased 550 shares for approximately $148,626 on June 22nd, increasing her personal stake by 14.44%.
📉 Analyst Robert W. Baird lowered its price target from $420 to $339 while maintaining an 'outperform' rating.
🏦 UBS Group raised its price target on Cencora from $410 to $412 and reaffirmed a 'buy' rating.
📈 The average analyst price target for the stock is currently set at $367.75 based on data from MarketBeat.com.
Return on equity reached 135.20% with positive net margin.
Revenue grew 3.9% year-over-year to $78.36 billion.
Institutional investors increased stakes, including JFS Wealth (+30.2%).
Paid quarterly dividend of $0.60 with 0.8% annualized yield.
Risk Factors
Missed EPS by 7 cents at $4.75 vs $4.82 consensus.
Revenue fell short at $78.36B vs $81.09B expectations.
Baird cut price target from $420 to $339.
Failed revenue guidance with $2.73B shortfall.
Bullish Signals
Cencora authorized a significant share buyback plan allowing the repurchase of up to $2.00 billion in shares, signaling management's confidence in the stock's value.
The company reported a strong return on equity of 135.20% and maintained a positive net margin of 0.78% despite missing revenue estimates.
Revenue grew by 3.9% year-over-year to $78.36 billion, demonstrating continued top-line expansion in the pharmaceutical distribution sector.
Multiple institutional investors increased their stakes in Q4, including JFS Wealth Advisors LLC (+30.2%) and Accent Capital Management LLC (+36.1%).
The company successfully paid a quarterly dividend of $0.60 per share with an annualized yield of 0.8%.
Risk Factors
Cencora missed first-quarter earnings estimates by seven cents per share, reporting $4.75 EPS against a consensus of $4.82.
Revenue of $78.36 billion fell short of analyst expectations of $81.09 billion for the quarter.
Analyst Robert W. Baird reduced its price target from $420 to $339, indicating some skepticism regarding current valuation levels.
The company failed to meet revenue guidance, reporting a shortfall of approximately $2.73 billion against analyst consensus.
Cencora, Inc. (formerly AmerisourceBergen) and its subsidiary The Lash Group have reached a definitive resolution regarding a massive data security incident that exposed the personal and protected health information of over 1.43 million individuals. Following months of litigation and administrative processing, a $40 million settlement fund has received final court approval from U.S. District Court Judge Cynthia M. Rufe on February 11, 2026. The distribution of funds to eligible claimants is scheduled to commence in July 2026.
The breach originated in February 2024 when unauthorized parties accessed Cencora's internal systems and moved between corporate networks and patient-facing databases managed by The Lash Group. The compromised data included sensitive information such as Social Security numbers, health histories, and contact details, creating significant risks for identity theft and medical fraud. The settlement addresses claims from the class action lawsuit Anaya, et al. v. Cencora, Inc., filed in the Eastern District of Pennsylvania.
The settlement offers two compensation paths: documented loss payments for individuals with verifiable financial harm incurred after September 1, 2023, capped at a total fund allocation of $5 million (up to $5,000 per individual), and cash fund payments for those who suffered privacy losses without specific out-of-pocket expenses. The cash payment amounts will be determined pro rata based on the remaining balance of the $40 million fund after all administrative costs and documented loss claims are deducted.
As part of the agreement, Cencora has committed to implementing enhanced data security measures funded separately from the settlement. The incident is viewed as a watershed moment for pharmaceutical supply chain security, highlighting the risks associated with shared network architectures between parent corporations and subsidiaries handling patient support services.
📜 Court approved $40M settlement on Feb 11, 2026 for 1.43M affected individuals.
💰 Payments start July 2026 after processing over 1.4 million claims.
📉 Breach exposed PHI via shared network including SSNs and health histories.
📝 Financial loss claimants get up to $5,000 with a $5M cap.
🔒 Cencora funds separate security upgrades beyond the settlement amount.
📜 Final court approval granted on February 11, 2026, for a $40 million settlement fund regarding the Cencora/The Lash Group data breach affecting over 1.43 million individuals.
💰 Payment distribution to eligible claimants is scheduled to commence in July 2026 following the completion of the claim processing phase.
📉 The breach involved unauthorized access via a shared network architecture, exposing sensitive PHI including Social Security numbers and health histories.
📝 Claimants with documented financial losses can receive up to $5,000 per individual, subject to a total cap of $5 million for this category.
💵 Cash fund payments for privacy loss are determined pro rata from the remaining balance after costs and documented loss claims are settled.
⚖️ The settlement resolves the class action lawsuit Anaya, et al. v. Cencora, Inc., filed in the Eastern District of Pennsylvania.
🔒 Cencora has committed to implementing enhanced data security measures funded separately from the $40 million settlement fund.
📅 The claims period closed on January 19, 2026; no new claims are being accepted for this specific incident.
🏢 The breach highlights third-party risk issues where a service provider's vulnerability compromises data held for drug manufacturers.
👥 Over 1.4 million potential class members require verification of claims, contributing to the extended timeline until July 2026.
Bullish Signals
Cencora reached definitive legal resolution with final court approval.
Company commits to enhanced security measures funded separately.
Settlement provides relief to over 1.43 million affected individuals.
Judge approved settlement as fair, reasonable, and adequate.
Intruders moved between corporate and patient databases via shared network.
Company settled to avoid litigation despite denying wrongdoing.
Payment delays expected until July 2026 for 1.4M claims.
$5M loss cap may reduce individual payouts pro rata.
Bullish Signals
Cencora has reached a definitive legal resolution with final court approval, ending years of uncertainty and litigation costs associated with the data breach.
The company is committing to implementing enhanced data and information security measures to prevent future incidents, funded separately from the settlement.
The settlement provides financial relief to over 1.43 million affected individuals through documented loss reimbursements and cash fund distributions.
Judge Cynthia M. Rufe approved the settlement as fair, reasonable, and adequate, validating the company's effort to resolve the matter without a trial.
Risk Factors
The breach exposed permanent data such as Social Security numbers and health histories, which cannot be changed like credit card numbers, creating long-term identity theft risks.
Cencora admitted unauthorized activity occurred through a shared network architecture that allowed intruders to move between corporate systems and patient-facing databases.
The company denied wrongdoing but settled to avoid continued litigation costs, indicating the severity of the security failure despite the denial.
Administrative processing for over 1.4 million claims is significant, with payment delays expected until July 2026 due to verification and auditing requirements.
The documented loss category has a strict cap of $5 million total, meaning individual payouts could be reduced on a pro rata basis if valid claims exceed this limit.
California Public Employees Retirement System (CalPERS) reduced its stake in Cencora, Inc. (NYSE:COR) by 12.5% during the first quarter, selling 61,988 shares to hold approximately 432,701 shares valued at $135.9 million. While CalPERS decreased its position, several other major institutional investors increased their holdings in the fourth quarter, including Vanguard Group, State Street Corp, T. Rowe Price Investment Management, Geode Capital Management, and JPMorgan Chase & Co., collectively signaling mixed but generally active institutional interest.
Cencora reported Q1 earnings of $4.75 per share, missing analyst consensus estimates of $4.82 by $0.07. The company generated revenue of $78.36 billion, which was 3.9% higher year-over-year but fell short of the estimated $81.09 billion. Despite the earnings miss, the firm maintains a market capitalization of $59.87 billion and has set full-year 2026 guidance between $17.65 and $17.90 per share, with analysts predicting an average consensus of $17.79.
The company recently announced a new stock repurchase program authorizing the purchase of up to $2.0 billion in shares, representing approximately 3.9% of its outstanding stock. Additionally, Cencora paid a quarterly dividend of $0.60 per share on June 1st, resulting in an annualized yield of 0.8%. Director Lauren M. Tyler also acquired 550 shares recently, increasing her direct ownership by 14.44% to 4,359 shares.
📉 CalPERS sold 61,988 shares, reducing stake to 432,701 worth $135.9M.
📈 Vanguard owns 23.6M shares valued at nearly $8 billion in Q4.
📈 T. Rowe Price raised position by 160.1%, adding over 4.1M shares.
💰 Revenue hit $78.36B (up 3.9%), missing estimates of $81.09B.
🔄 New buyback program authorizes purchase of up to $2.0 billion.
📉 CalPERS reduced its stake in Cencora by 12.5% in Q1, selling 61,988 shares while holding 432,701 shares valued at $135.9 million.
📈 Vanguard Group increased its stake by 0.9% to own 23.6 million shares worth nearly $8 billion in the fourth quarter.
📈 T. Rowe Price Investment Management significantly raised its position by 160.1%, acquiring over 4.1 million additional shares.
📉 Cencora reported Q1 EPS of $4.75, missing analyst estimates of $4.82 by $0.07.
💰 The company generated revenue of $78.36 billion for the quarter, representing a 3.9% year-over-year increase.
📉 Revenue missed analyst expectations of $81.09 billion during the first quarter reporting period.
🔄 Cencora announced a new stock repurchase program authorizing the buyback of up to $2.0 billion in shares.
💵 The firm paid a quarterly dividend of $0.60 per share with an annualized yield of 0.8%.
📊 Analysts maintain an average price target of $367.75, though Wells Fargo and Barclays recently lowered their targets.
👤 Director Lauren M. Tyler purchased 550 shares at an average cost of $270.23, increasing her direct ownership stake.
Bullish Signals
Major investors like Vanguard and JPMorgan Chase increased stakes.
T. Rowe Price added 4 million shares, up 160.1%.
$2.0 billion stock repurchase program announced by management.
Arcus Capital Partners LLC established a new $678,000 position in Cencora, Inc. (NYSE:COR) during the first quarter, joining several other institutional investors like Kemnay Advisory and Oakworth Capital who also initiated or increased stakes in the fourth quarter. Hedge funds collectively own 97.52% of the company's stock, indicating significant institutional interest despite recent analyst rating adjustments.
Analyst sentiment remains mixed with a consensus 'Moderate Buy' rating and an average price target of $367.75. While Morgan Stanley and Evercore maintain bullish targets around $342-$360, Barclays and Robert W. Baird recently lowered their price targets to $350 and $339 respectively, and Weiss Ratings downgraded the stock from a 'buy' to a 'hold'.
Financially, Cencora reported Q1 EPS of $4.75, missing analyst estimates by $0.07, with revenue of $78.36 billion growing 3.9% year-over-year but falling short of the $81.09 billion consensus. The company has set FY 2026 guidance between $17.65 and $17.90 EPS, slightly below analyst predictions of $17.79.
The company announced a $2.00 billion share repurchase program approved by its Board of Directors on May 21st, allowing the purchase of up to 3.9% of outstanding shares. Additionally, Cencora paid a quarterly dividend of $0.60 per share on June 1st, with an annualized yield of 0.8% and a payout ratio of 18.40%.
📈 Arcus Capital bought $678,000 new position in Q1.
📉 Barclays and Baird cut price targets to $350 and $339.
💰 Q1 revenue rose 3.9% to $78.36 billion despite missing EPS.
🔄 Board approved $2.00 billion share repurchase program on May 21.
💵 Quarterly dividend of $0.60 paid June 1st with 0.8% yield.
📈 Arcus Capital Partners LLC purchased a new position in Cencora valued at approximately $678,000 during the first quarter.
📉 Barclays and Robert W. Baird recently cut their price targets to $350.00 and $339.00 respectively, while Weiss Ratings downgraded the stock from 'buy' to 'hold'.
💰 Cencora reported Q1 revenue of $78.36 billion, a 3.9% increase year-over-year, though it missed analyst EPS estimates by $0.07.
🔄 The company's Board of Directors approved a new $2.00 billion share repurchase program authorized on May 21st.
💵 Investors received a quarterly dividend of $0.60 per share paid on June 1st, representing an annualized yield of 0.8%.
📊 The stock currently trades with a market cap of $59.87 billion and a PE ratio of 23.60, trading above its 50-day moving average.
👥 Director Lauren M. Tyler increased her personal stake by 14.44% in June, purchasing 550 shares for a total transaction of $148,626.50.
📈 Hedge funds and institutional investors own 97.52% of Cencora's outstanding stock as of the latest filings.
Bullish Signals
Announced $2.00 billion share repurchase program.
Revenue grew 3.9% year-over-year to $78.36 billion.
Institutional ownership stands at 97.52% with new investors.
Stock trades above 50-day moving average of $279.98.
Risk Factors
Missed Q1 EPS by $0.07, reporting $4.75 vs $4.82 consensus.
Revenue fell short at $78.36B vs $81.09B expectations.
Barcut target from $425 to $350; Baird cut to $339.
Weiss downgraded stock from 'buy' to 'hold' in late June.
Bullish Signals
Cencora announced a $2.00 billion share repurchase program, signaling management's confidence in the stock's undervaluation and commitment to returning capital to shareholders.
The company reported revenue growth of 3.9% year-over-year to $78.36 billion, demonstrating continued expansion in its pharmaceutical distribution business despite missing EPS estimates.
Institutional ownership remains extremely high at 97.52%, with multiple new investors like Arcus Capital and Kemnay Advisory initiating positions in the first and fourth quarters.
The stock trades above its 50-day moving average of $279.98, suggesting short-term technical strength despite being below its 200-day moving average.
Risk Factors
Cencora missed Q1 analyst EPS estimates by $0.07, reporting $4.75 compared to the consensus of $4.82.
Revenue of $78.36 billion fell short of analyst expectations of $81.09 billion for the quarter.
Several major analysts recently lowered price targets, with Barclays cutting from $425 to $350 and Robert W. Baird reducing their target to $339.
Weiss Ratings downgraded the stock from a 'buy (b-)' rating to a 'hold (c+)' rating in late June.
Allspring Global Investments Holdings LLC increased its stake in Cencora, Inc. (NYSE:COR) by 7.8% during the first quarter, acquiring an additional 29,983 shares to hold a total of 413,051 shares valued at $131.21 million. This represents a 0.21% ownership stake in the company. Several other institutional investors also adjusted their positions in the fourth quarter, with Kemnay Advisory Services Inc., Oakworth Capital Inc., Elyxium Wealth LLC, and Motiv8 Investments LLC all establishing new stakes valued between $25,000 and $29,000. Archer Investment Corp significantly increased its holdings by 134.3%, bringing its total stake to 82 shares worth $28,000.
Cencora reported quarterly earnings on May 6th, posting EPS of $4.75 against analyst expectations of $4.82, resulting in a miss of $0.07 per share. The company generated revenue of $78.36 billion for the quarter, which was slightly below the estimated $81.09 billion but represented a 3.9% year-over-year increase. Key financial metrics included a return on equity of 135.20% and a net margin of 0.78%. The company has provided full-year 2026 earnings guidance ranging between $17.65 and $17.90 per share, while analysts currently anticipate an EPS of $17.79.
The Board of Directors approved a new share repurchase program on May 21st, authorizing the company to buy back up to $2.00 billion in outstanding shares, which equates to approximately 3.9% of its stock. Additionally, Cencora paid a quarterly dividend of $0.60 per share on June 1st for shareholders of record as of May 15th, resulting in an annualized yield of 0.8%. Director Lauren M. Tyler also purchased 550 shares at an average price of $270.23, increasing her personal ownership by 14.44% to a total of 4,359 shares valued at over $1.17 million.
📈 Allspring raised Cencora holdings by 7.8% to 413,051 shares in Q1.
💰 Quarterly revenue reached $78.36 billion, up 3.9% year-over-year.
📉 Q1 EPS of $4.75 missed analyst consensus estimates by $0.07.
🔄 Board approved a $2.0 billion share repurchase program.
🎯 Consensus target price is $367.75 with a 'Moderate Buy' rating.
📈 Allspring Global Investments Holdings LLC raised its Cencora holdings by 7.8% in Q1, adding 29,983 shares to a total position of 413,051 shares.
🏦 Multiple institutional investors including Kemnay Advisory Services Inc., Oakworth Capital Inc., and Motiv8 Investments LLC established new stakes valued between $25,000 and $29,000 in Q4.
📉 Cencora reported Q1 EPS of $4.75, missing analyst consensus estimates of $4.82 by $0.07 per share.
💰 The company generated quarterly revenue of $78.36 billion, a 3.9% increase compared to the same quarter in the prior year.
📊 Cencora achieved a return on equity of 135.20% and maintained a net margin of 0.78% during the reported quarter.
🔄 The Board of Directors approved a $2.00 billion share repurchase program, allowing the purchase of up to 3.9% of outstanding shares.
💵 Cencora paid a quarterly dividend of $0.60 per share on June 1st, offering an annualized yield of 0.8%.
👔 Director Lauren M. Tyler purchased 550 shares for $148,626.50, increasing her personal ownership by 14.44% to 4,359 shares.
📉 Robert W. Baird reduced its price target from $420.00 to $339.00 while maintaining an 'outperform' rating.
📉 Citigroup lowered its price target from $405.00 to $355.00 but retained a 'buy' rating for the stock.
📉 Wells Fargo & Company cut its price objective from $429.00 to $331.00 with an 'overweight' rating.
📈 Bank of America increased its target price from $280.00 to $285.00 and issued a 'neutral' rating.
🎯 The consensus analyst target price for Cencora is currently set at $367.75 with an average rating of 'Moderate Buy'.
🏢 Hedge funds and other institutional investors collectively own 97.52% of the company's outstanding stock.
📈 Insider ownership stands at 0.38%, with Director Lauren M. Tyler holding a significant portion of that stake.
Bullish Signals
Archer Investment Corp increased holdings by 134.3% in Q4.
Cencora approved a $2.00 billion share repurchase program.
Quarterly dividend of $0.60 with 0.8% annualized yield.
Director Lauren M. Tyler ownership increased by 14.44%.
Revenue grew 3.9% year-over-year to $78.36 billion.
Risk Factors
EPS missed estimates at $4.75 vs $4.82 consensus.
Revenue fell short at $78.36B vs $81.09B expected.
Major analysts cut targets: Baird to $339, Citi to $355.
Wells Fargo lowered target from $429 to $331.
Bullish Signals
Allspring Global Investments Holdings LLC increased its position by 7.8% in Q1, signaling continued institutional confidence in the company.
Several other large investors, including Kemnay Advisory Services Inc., Oakworth Capital Inc., and Motiv8 Investments LLC, established new positions valued between $25,000 and $29,000 in Q4.
Archer Investment Corp significantly increased its holdings by 134.3% in Q4, demonstrating strong bullish sentiment from a specific investor.
Cencora approved a substantial $2.00 billion share repurchase program, indicating management's belief that the stock is undervalued and a commitment to returning capital to shareholders.
The company paid a quarterly dividend of $0.60 per share on June 1st, providing income to shareholders with an annualized yield of 0.8%.
Director Lauren M. Tyler purchased 550 shares for $148,626.50, increasing her personal ownership by 14.44%, which often signals insider confidence in the company's future prospects.
Cencora achieved a robust return on equity of 135.20% and maintained a positive net margin of 0.78% despite missing earnings estimates.
Revenue grew by 3.9% year-over-year to $78.36 billion, demonstrating consistent top-line growth in the pharmaceutical distribution sector.
Risk Factors
Cencora missed quarterly earnings estimates, reporting EPS of $4.75 against analyst consensus of $4.82, a miss of $0.07 per share.
Quarterly revenue of $78.36 billion fell short of analyst expectations of $81.09 billion, indicating potential headwinds in the distribution market.
Multiple major analysts reduced their price targets, with Robert W. Baird cutting from $420.00 to $339.00, Citigroup from $405.00 to $355.00, and Wells Fargo from $429.00 to $331.00.
The consensus analyst target price of $367.75 is significantly below the recent high price targets mentioned by analysts like Robert W. Baird ($420.00) and Citigroup ($405.00), suggesting a downward revision in valuation expectations.
Bleakley Financial Group LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 39.4% in the first quarter, selling 11,082 shares to hold a remaining position of 17,020 shares valued at approximately $5.35 million. This move contrasts with several other institutional investors who increased their holdings in the fourth quarter, including JFS Wealth Advisors LLC, Apollon Wealth Management LLC, Accent Capital Management LLC, MCF Advisors LLC, and CYBER HORNET ETFs LLC, which collectively raised their stakes by varying percentages ranging from 0.5% to 36.1%.
Analyst sentiment remains mixed but generally positive regarding the stock's valuation potential. Major financial institutions have issued updated price targets and ratings in recent months; for instance, Wells Fargo lowered its target to $331 with an 'overweight' rating, while Bank of America raised its target to $285 with a 'neutral' rating. The consensus average rating from eleven equities research analysts is currently a 'Moderate Buy' with a collective price target of $367.75.
Financially, Cencora reported Q1 earnings of $4.75 per share, missing the consensus estimate of $4.82 by seven cents, while revenue reached $78.36 billion, slightly below the expected $81.09 billion but up 3.9% year-over-year. The company has initiated a $2.00 billion stock repurchase plan and recently paid a quarterly dividend of $0.60 per share, yielding 0.8%. Insider activity includes Director Lauren M. Tyler purchasing 550 shares for approximately $148,626 in late June.
Cencora operates as a global healthcare services and pharmaceutical distribution company providing end-to-end solutions across the pharmaceutical supply chain. Its core activities include wholesale and specialty drug distribution, alongside logistics and cold-chain management for temperature-sensitive therapies. The firm also offers commercial and patient-focused services to pharmaceutical manufacturers and healthcare providers, maintaining a market capitalization of $58.79 billion.
📉 Bleakley Financial reduced Cencora stake by 39.4% in Q1.
📈 Accent Capital and JFS Wealth increased holdings significantly in Q4.
💰 Q1 revenue hit $78.36 billion, up 3.9% year-over-year.
🔄 Board authorized new $2.0 billion stock repurchase plan.
💵 Quarterly dividend of $0.60 yields 0.8% annually.
📉 Bleakley Financial Group LLC reduced its stake in Cencora by 39.4% in Q1, selling 11,082 shares while retaining 17,020 shares valued at $5.35 million.
📈 Multiple institutional investors increased their positions in Q4, with Accent Capital Management LLC raising its stake by 36.1% and JFS Wealth Advisors LLC growing its holding by 30.2%.
💰 Cencora reported Q1 revenue of $78.36 billion, representing a 3.9% year-over-year increase despite missing the consensus EPS estimate by $0.07.
📊 Analyst consensus targets the stock at $367.75 with an average rating of 'Moderate Buy' based on reports from major firms like Wells Fargo and Bank of America.
🔄 The company announced a new $2.00 billion stock repurchase plan authorized by its board to buy up to 3.9% of outstanding shares.
💵 Shareholders received a quarterly dividend of $0.60 per share, resulting in an annualized yield of 0.8% and a payout ratio of 18.40%.
👔 Insider activity saw Director Lauren M. Tyler purchase 550 shares for approximately $148,626, increasing her direct ownership by 14.44%.
📉 The stock currently trades at a P/E ratio of 23.17 with a market capitalization of $58.79 billion and a beta of 0.58.
🏥 Cencora operates as a global leader in pharmaceutical distribution, managing wholesale drug supply chains and specialty pharmacy operations.
📉 The stock recently opened at $302.16, trading above its 50-day moving average of $277.12 but below its 200-day average of $318.31.
Bullish Signals
Cencora initiates $2.0B stock repurchase plan.
Revenue grew 3.9% YoY to $78.36B.
Analysts rate 'Moderate Buy' with $367.75 target.
Director Tyler increased ownership by 14.44%.
Risk Factors
Revenue of $78.36B missed analyst consensus of $81.09B.
Stock trades below 200-day moving average of $318.31.
Liquidity concerns with current ratio of 0.95 and quick ratio of 0.59.
Bullish Signals
Cencora initiated a $2.00 billion stock repurchase plan, signaling management's belief that the stock is undervalued and demonstrating commitment to returning capital to shareholders.
The company reported revenue growth of 3.9% year-over-year to $78.36 billion, indicating continued expansion in its core pharmaceutical distribution business despite missing earnings estimates.
Analyst consensus maintains a 'Moderate Buy' rating with an average price target of $367.75, suggesting potential upside from current levels as major banks like Wells Fargo and Bank of America maintain positive or neutral outlooks.
Director Lauren M. Tyler increased her direct ownership by 14.44% through a significant purchase of 550 shares, indicating insider confidence in the company's future prospects.
Risk Factors
Revenue of $78.36 billion fell short of the analyst consensus estimate of $81.09 billion, indicating a slight miss in top-line growth expectations for the quarter.
The stock trades below its 200-day simple moving average of $318.31, suggesting some near-term weakness or consolidation relative to longer-term trends.
The current ratio of 0.95 and quick ratio of 0.59 indicate liquidity constraints that could be a concern if cash flow dynamics deteriorate further in the coming quarters.
First Horizon Corp reduced its stake in Cencora, Inc. (NYSE:COR) by 36.5% during the first quarter, selling 3,747 shares to hold a remaining position of 6,506 shares valued at $2,044,000. This move contrasts with several other institutional investors who increased their holdings in the second quarter, including United Bank, Nebula Research & Development LLC, and DZ BANK AG, which collectively added significant capital to their positions.
Analyst sentiment remains mixed but generally positive regarding Cencora's long-term prospects. Major banks like Morgan Stanley and Evercore maintain high price targets of $342 and $360 respectively, while Bank of America raised its target to $285 with a neutral rating. Conversely, Robert W. Baird lowered its target to $339, and Barclays cut its target to $350, though both maintained buy or overweight ratings.
Financially, Cencora reported Q1 earnings of $4.75 EPS, missing the consensus estimate of $4.82, with revenue of $78.36 billion falling short of the $81.09 billion expectation. Despite the miss, the company grew revenue by 3.9% year-over-year and maintains a robust return on equity of 135.20%. The firm has initiated a $2.00 billion stock repurchase program and pays a quarterly dividend of $0.60.
The company operates as a global leader in healthcare services and pharmaceutical distribution, providing end-to-end solutions including wholesale drug distribution, specialty pharmacy operations, and cold-chain management for temperature-sensitive therapies. With a market capitalization of $59.01 billion and an average analyst target price of $367.75, the stock trades above its 50-day moving average but below its 200-day moving average.
📉 First Horizon Corp trimmed Cencora position by 36.5% in Q1.
📈 United Bank increased stake; DZ BANK AG boosted by 26%.
💰 Cencora announced $2.0 billion stock repurchase plan authorized May 21.
📊 Q1 revenue hit $78.36 billion, up 3.9% year-over-year.
🎯 Analyst consensus is Moderate Buy with $367.75 price target.
📉 First Horizon Corp trimmed its Cencora position by 36.5% in Q1, reducing holdings to 6,506 shares worth $2.04 million.
📈 United Bank increased its stake by 4.5% in Q2, while DZ BANK AG boosted its position by 26.0% to own $22.025 million in stock.
💰 Cencora announced a new $2.00 billion stock repurchase plan authorized by the Board of Directors on May 21st.
📊 The company reported Q1 revenue of $78.36 billion, up 3.9% year-over-year, though it missed EPS estimates by $0.07.
🎯 Analyst consensus remains a 'Moderate Buy' with an average price target of $367.75, despite mixed individual bank targets ranging from $285 to $420.
💵 Cencora paid a quarterly dividend of $0.60 on June 1st, representing a 0.8% yield and an 18.40% payout ratio.
👔 Director Lauren M. Tyler purchased 550 shares at $270.23 per share, increasing her personal ownership by 14.44%.
📉 The stock currently trades at a P/E ratio of 23.26 with a market cap of $59.01 billion and a beta of 0.58.
🏥 Cencora provides critical pharmaceutical distribution, specialty pharmacy services, and cold-chain logistics for temperature-sensitive therapies.
Bullish Signals
Cencora initiated a $2.00 billion stock repurchase program.
Revenue grew by 3.9% year-over-year to $78.36 billion.
Company maintains an exceptionally high return on equity of 135.20%.
Major institutional investors increased their stakes significantly in Q2.
Analysts maintain a 'Moderate Buy' consensus with a $367.75 target.
Risk Factors
Missed Q1 earnings by $0.07, reporting $4.75 EPS vs $4.82 consensus.
Revenue fell short at $78.36B vs $81.09B analyst expectations.
Stock trades below 200-day moving average of $318.98.
Tight liquidity with current ratio of 0.95 and quick ratio of 0.59.
Bullish Signals
Cencora initiated a $2.00 billion stock repurchase program, signaling management's belief that shares are undervalued.
Revenue grew by 3.9% year-over-year to $78.36 billion, demonstrating continued top-line expansion despite missing earnings estimates.
The company maintains an exceptionally high return on equity of 135.20%, indicating strong capital efficiency.
Major institutional investors like DZ BANK AG and United Bank increased their stakes significantly in the second quarter.
Analysts maintain a 'Moderate Buy' consensus with an average price target of $367.75, which is above the current trading price.
Risk Factors
Cencora missed Q1 earnings expectations by $0.07 per share, reporting $4.75 EPS against a consensus of $4.82.
Revenue of $78.36 billion fell short of analyst expectations of $81.09 billion for the quarter.
The stock trades below its 200-day moving average of $318.98, indicating some near-term weakness relative to longer-term trends.
Current liquidity ratios are tight, with a current ratio of 0.95 and a quick ratio of 0.59.
Cencora (COR) is recommended for holding by Zacks Investment Research, which assigns it a Rank #3. The company has outperformed its industry and the S&P 500 over the past six months, gaining 18.9% compared to minimal industry growth. As one of the world's largest pharmaceutical service companies, Cencora focuses on drug distribution and related services to reduce healthcare costs and improve patient outcomes.
The company is strengthening its position through vertical integration into high-margin Medical Specialty Organizations (MSOs), specifically via the OneOncology acquisition. Management has raised its fiscal 2026 guidance, projecting 7-9% revenue growth and 11.5–13.5% operating income growth. Specifically, U.S. Healthcare Solutions operating income growth was upgraded to 14-16%, reflecting strong execution despite customer losses.
Cencora demonstrated resilience in pricing dynamics, maintaining gross profit dollars despite regulatory-driven list price reductions through successful contract renegotiations. However, the company faces risks including a 14% decline in international segment operating income due to timing-related pricing adjustments and ongoing headwinds from customer losses, such as the exit of a large oncology client.
Analysts note integration risks associated with MSO acquisitions, which are expected to be EPS-neutral in the first 12 months. Additionally, Cencora has seen a negative trend in analyst estimate revisions for fiscal 2026, with consensus earnings per share decreasing slightly. The article concludes by comparing Cencora's performance and growth estimates against peers like Intuitive Surgical, Align Technology, and Cardinal Health.
📈 Zacks ranks Cencora Hold after 18.9% share gain vs 0.4% industry growth.
🚀 Management raised fiscal 2026 guidance to 7-9% revenue and 11.5–13.5% operating income growth.
💊 OneOncology acquisition shifts focus to high-margin MSOs with differentiated service revenue.
⚠️ International Healthcare Solutions operating income declined 14% due to pricing adjustments.
📉 Consensus fiscal 2026 earnings estimate decreased to $17.59 per share.
📈 Zacks Investment Research assigns Cencora a Rank #3 (Hold) after shares gained 18.9% in the past six months versus 0.4% industry growth.
🚀 Management raised fiscal 2026 guidance to expect 7-9% revenue growth and 11.5–13.5% operating income growth driven by U.S. segment strength.
💊 The OneOncology acquisition enhances vertical integration into high-margin MSOs, shifting the company toward differentiated service-oriented revenue streams.
🛡️ Cencora maintained gross profit dollars despite regulatory list price reductions through successful contract renegotiations with manufacturers.
⚠️ International Healthcare Solutions operating income declined 14% due to timing-related pricing adjustments in certain markets.
📉 The company faces headwinds from customer losses, including the exit of a large oncology customer acquired by a competitor.
🔄 Acquisitions like OneOncology are expected to be EPS-neutral in the first 12 months due to integration complexity and limited immediate earnings accretion.
📉 Cencora has witnessed a negative estimate revision trend, with the Zacks Consensus Estimate for fiscal 2026 earnings decreasing to $17.59 per share.
🔍 Analysts highlight execution risks in aligning physician networks and systems while scaling the MSO footprint across multiple specialties.
📊 Peer comparison shows Cardinal Health (CAH) rallied 45% over six months, while Cencora's long-term growth is anticipated to improve 12.2%.
Bullish Signals
Shares gained 18.9% vs industry's 0.4% and S&P 500's 1.8%.
Raised fiscal 2026 guidance: 7-9% revenue, 11.5–13.5% operating income growth.
U.S. Healthcare Solutions operating income growth increased to 14-16%.
Maintained gross profit dollars despite list price reductions via renegotiations.
Bottom line anticipated to improve 12.2% over next five years.
Risk Factors
Operating income down 14% from pricing adjustments.
Lost large oncology customer to competitor acquisition.
OneOncology EPS-neutral for first 12 months post-acquisition.
Consensus EPS revised down to $17.59 for FY2026.
Revenue instability from healthcare provider consolidation.
Bullish Signals
Cencora shares have gained 18.9% in the past six months compared to the industry's 0.4% growth and the S&P 500's 1.8% gain.
Management raised fiscal 2026 guidance, now expecting 7-9% revenue growth and 11.5–13.5% operating income growth driven by continued strength in the U.S. segment.
U.S. Healthcare Solutions operating income growth guidance was notably increased to 14-16%, reflecting strong execution despite customer losses.
The company demonstrated resilience in pricing dynamics, maintaining gross profit dollars despite list price reductions tied to regulatory changes through successful contract renegotiations.
Expansion into pharmaceutical-centric MSOs, particularly through the OneOncology acquisition, enhances vertical integration and provides high-margin revenue streams.
Cencora's bottom line is anticipated to improve 12.2% over the next five years with earnings beating estimates in each of the trailing four quarters.
Risk Factors
The International Healthcare Solutions segment reported a 14% decline in operating income primarily due to timing-related pricing adjustments in certain markets.
Cencora continues to face headwinds from customer losses, including the exit of a large oncology customer due to acquisition by a competitor.
Analysts note integration risks and limited near-term EPS contribution from acquisitions, with OneOncology expected to be EPS-neutral in the first 12 months.
Cencora has been witnessing a negative estimate revision trend for fiscal 2026, with the consensus earnings per share decreasing by 1 cent to $17.59.
The exit of large distribution contracts due to customer consolidation underscores exposure to healthcare provider consolidation and potential revenue stream instability.
Cencora, Inc. (NYSE:COR) recently reported its quarterly earnings, posting $4.75 per share in EPS against a consensus estimate of $4.82, resulting in a miss of $0.07. The company generated revenue of $78.36 billion for the quarter, representing a 3.9% year-over-year increase compared to the estimated $81.09 billion. Despite missing earnings expectations, the firm maintains a strong return on equity of 135.20% and has set full-year 2026 guidance between $17.65 and $17.90 per share.
Institutional interest in Cencora remains active with several hedge funds adjusting their positions. Ascentis Independent Advisors increased its stake by 109.0% to own 4,399 shares valued at $1.382 million. Other notable activity includes Kemnay Advisory Services, Oakworth Capital Inc., and Elyxium Wealth LLC establishing new stakes in the fourth quarter, while Archer Investment Corp lifted its position significantly.
Analyst sentiment is mixed with a consensus 'Moderate Buy' rating and an average target price of $367.75. UBS Group raised its price objective to $412.00 with a 'buy' rating, whereas Wells Fargo & Company lowered its target to $331.00 while maintaining an 'overweight' rating. The company also announced a new $2.00 billion share buyback plan approved by the Board of Directors and paid a quarterly dividend of $0.60 per share.
📉 Q1 EPS missed estimates at $4.75 vs $4.82 consensus.
💰 Revenue hit $78.36B, up 3.9% year-over-year.
🏦 Multiple hedge funds established new positions in Q4.
💸 Board approved a new $2.0 billion share buyback plan.
🎯 Analysts rate stock 'Moderate Buy' with $367.75 target price.
📉 Cencora reported Q1 EPS of $4.75, missing analyst consensus estimates of $4.82 by $0.07.
💰 Quarterly revenue reached $78.36 billion, up 3.9% year-over-year against a consensus of $81.09 billion.
📈 Ascentis Independent Advisors raised its stake in Cencora by 109.0% to own 4,399 shares worth $1.382 million.
🏦 Multiple hedge funds including Kemnay Advisory Services and Oakworth Capital Inc. established new positions in the fourth quarter.
📊 The stock carries a market cap of $58.13 billion with a PEG ratio of 1.65 and a beta of 0.58.
🎯 Analyst consensus rating is 'Moderate Buy' with an average target price of $367.75 based on MarketBeat data.
📈 UBS Group increased its price objective to $412.00 and reaffirmed a 'buy' rating for the stock.
📉 Wells Fargo & Company cut its price objective to $331.00 but maintained an 'overweight' rating.
💸 The company announced a new $2.00 billion share buyback plan approved by the Board of Directors.
💰 A quarterly dividend of $0.60 per share was paid on June 1st with an annualized yield of 0.8%.
📉 The stock currently trades above its 50-day moving average but below its 200-day moving average.
🏢 Cencora operates as a global healthcare services and pharmaceutical distribution company with a market cap of $58.13 billion.
Bullish Signals
Revenue reached $78.36 billion with 3.9% growth.
Return on equity stands at 135.20%.
Ascentis Advisors increased position by 109.0%.
UBS raised target to $412.00 with 'buy' rating.
Board approved $2.00 billion share buyback plan.
Risk Factors
Missed earnings by $0.07; reported $4.75 EPS vs $4.82 consensus.
Wells Fargo cut price target from $429 to $331.
Trading below 200-day moving average of $319.86.
Revenue of $78.36B missed $81.09B consensus estimate.
Bullish Signals
Cencora generated revenue of $78.36 billion, achieving a 3.9% year-over-year growth rate.
The company maintains a high return on equity of 135.20%, indicating strong capital efficiency.
Ascentis Independent Advisors significantly increased its position by 109.0%, signaling institutional confidence.
UBS Group raised its price target to $412.00 and issued a 'buy' rating on the stock.
The Board of Directors approved a substantial $2.00 billion share buyback plan, suggesting management views shares as undervalued.
Analyst consensus remains positive with an average target price of $367.75 and a 'Moderate Buy' rating.
Risk Factors
Cencora missed quarterly earnings expectations by $0.07 per share, reporting $4.75 EPS versus the $4.82 consensus.
Wells Fargo & Company lowered its price objective from $429.00 to $331.00, reflecting some analyst caution.
The stock currently trades below its 200-day simple moving average of $319.86, indicating potential short-term weakness.
Revenue of $78.36 billion came in below the consensus estimate of $81.09 billion for the quarter.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)